Advice
following an abbreviated submission:
azithromycin (Zedbac®) is accepted for use within NHS Scotland.
Indication under review: the treatment of community acquired pneumonia (CAP) and pelvic inflammatory disease (PID) due to susceptible organisms in adult patients where initial intravenous therapy is required.
Consideration should be given to official guidance regarding the appropriate use of antibacterial agents.
This is the first intravenous formulation of azithromycin to be made available in the UK.
The intravenous formulation is significantly more expensive than the oral preparation of azithromycin, but it is intended only for short-term use and on the advice of local microbiologists or specialists in infectious diseases.
Download detailed advice40KB (PDF)
Medicine details
- Medicine name:
- azithromycin (Zedbac)
- SMC ID:
- 950/14
- Indication:
- The treatment of community acquired pneumonia (CAP) and pelvic inflammatory disease (PID) due to susceptible organisms in adult patients where initial intravenous therapy is required.
- Pharmaceutical company
- Aspire Pharma Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 April 2014